Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]

ConclusionsSimilar PK profiles and robust LDL‐C reductions were observed following a single 150‐mg s.c. injection of bococizumab administered to the abdomen, thigh, or upper arm in untreated subjects with LDL‐C ≥130 mg/dL. Bococizumab was generally well tolerated following a single 150‐mg s.c. administration in this subject population.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research